FALCON is a Phase 3 clinical study evaluating the effectiveness and safety of bardoxolone methyl (an oral investigational drug) in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
You may be eligible for this study if you:
Are 18 to 70 years of age
Have been diagnosed with ADPKD
**Other eligibility criteria will apply**
The investigational drug, study-related procedures, and doctor visits will be provided at no cost. If you travel to the site for your study visits, travel expenses will be reimbursed, and compensation for study- related time may be provided.
If you’re interested in participating in one of our Research Studies:
303-232-3366 ext 2170